Source
Rare Disease Advisor
The modified-comprehensive Kumamoto Score (mKS) can be used as a validated comprehensive tool for the assessment of hereditary transthyretin amyloidosis (ATTR), according to a new study published in Amyloid.
The score also has enhanced early-stage sensitivity and offers independent subscales specific to different organs, therefore addressing critical unmet needs.
To develop and validate mKS, a team of researchers led by Mitsuharu Ueda, MD, from Kumamoto University in Japan conducted a prospective study of 76 patients with genetically confirmed ATTR. The median age of patients was 56.2 years, and the majority (60.5% of all patients) had the Val30Met mutation.
News Url